Clinical Characteristics among Patients with Hepatocellular Carcinoma According to the Serum Levels of α-fetoprotein and Des-γ-carboxy Prothrombin

Hepato-Gastroenterology

Volumn 50, Issue 54, 2003, Pages 2072-2078

  Dohmen, Kazufumi ^a   Shigematsu, Hirohisa ^b   Irie, Koji ^b   Ishibashi, Hiromi ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b Saga Prefectural Hospital   (Japan)

Author keywords

Alpha fetoprotein; Des carboxy prothrombin; Hepatocellular carcinoma; PIVKA II; Platelet; Portal thrombosis

Indexed keywords

ALPHA FETOPROTEIN; PROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; JAPAN; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; PORTAL VEIN; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 0344961316     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Eng J Med 1999; 340:745-750.
2. Maringhini A, Cottone M, Sciarrino E, et al: Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci 1988; 33:47-51.
3. Taketa K, Sekiya C, Namiki M, et al: Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990; 99:506-518.
4. Yamashita F, Tanaka M, Satomura S, et al: Monitoring of lectin-reactive α-fetoprotein in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Eur J Gastroenterol Hepatol 1995; 7:627-633.
5. Fujiyama S, Izuno K, Gohshi K, et al: Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci 1991; 36:1787-1792.
6. Kasahara A, Hayashi N, Fusamoto H, et al: Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993; 38:2170-2176.
7. Kuromatsu R, Tanaka M, Shimauchi Y, et al: Usefuness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma. J Gastroenterol 1997; 32:507-512.
8. Tanaka Y, Kashiwagi T, Tsutsumi H, et al: Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma. Hepatogastroenterology 1999; 46:2464-2468.
9. Mita Y, Aoyagi Y, Yanagi M, et al: The usefulness of determing des-γ-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82:1643-1648.
10. Okuda H, Nakanishi T, Takatsu K, et al: Measurement of serum levels of des-γ-carboxy prothrombin inpatients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999; 85:812-818.
11. Okuda H, Nakanishi T, Takatsu K, et al: Serum levels of des-γ-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000; 88:544-549.
12. Koike Y, Shiratori Y, Sato S, et al: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91:561-569.
13. Suehiro T, Sugimachi K, Matsumata T, et al: Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma - comparison with alpha-fetoprotein. Cancer 1994; 73:2464-2471.
14. Aoyagi Y, Oguro M, Yanagi M, et al: Clinical significance of simultaneous determination of alpha-fetoprotein and desgammma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996; 77:1781-1786.
15. Okuda H, Obata H, Nakanishi T, et al: Production of abnormal prothrombin (des-γ-carboxy prothrombin) by hepatocellular carcinoma: a clinical and experimental study. J Hepatol 1987; 4:357-363.
16. Okuda H, Nakanishi T, Furukawa M, et al: Vitamin K-dependent proteins and hepatocellular carcinoma. J Gastroenteol Hepatol 1991; 6:392-399.
17. Yamagata H, Nakanishi T, Furukawa M, et al: Levels of vitamin K, immunoreactive prothrombin, des-γ-carboxy prothrombin and y-glutamyl carboxylase activity in hepatocellular carcinoma tissue. J Gastroenterol Hepatol 1995; 10:8-13.
18. Nakagawa T, Seki T, Shiro T, et al: Clinicopathologic significance of protein induced vitamin K absence or antagonist II and α-fetoprotein in hepatocellular carcinoma. Int J Oncol 1999; 14:281-286.
19. Johnson PJ, Melia WM, Palmer MK, et al: Relationship between serum alpha-fetoprotein, cirrhosis, and survival in hepatocellular carcinoma. Br J Cancer 1981; 44:502-505.
20. Shirabe K, Takenaka K, Gion T, et al: Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol 1997; 64:143-146.
21. Shimada M, Takenaka K, Fujiwara Y, et al: Des-γ-carboxy prothrombin and alpha-fetoprotein AFP/DCP status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996; 78:2094-2100.
22. Hamamura K, Shiratori Y, Shiina S, et al: Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum α-fetoprotein. Cancer 2000; 88:1557-1564.
23. Okuda H, Nakanishi T, Takatsu K, et al: Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for α-fetoprotein alone and these seropositive for des-γ-carboxy prothrombin alone. J Gastoenterol Hepatol 2001; 16:1290-1296.
24. Edmondson HA, Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7:462-503.
25. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53:457-481.
26. Guo L, Kuroda N, Toi M, et al: Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis. Oncology Rep 2001; 8:871-876.
27. Stubbs MT, Bode W: A player of many parts: the spotlight falls on thrombin structure. Thromb Res 1993; 69:1-58.
28. Bar-Sharit R, Wilner GD: Biologic activities of nonenzymatic thrombin: elucidation of a macrophage interactive domain. Sem Thromb Hemost 1986; 12:244-249.
29. Suehiro T, Matsumata T, Itasaka H, et al: Des-gamma-carboxy prothrombin and proliferative activity of hepatocel-lular carcinoma. Surgery 1995; 117:682-691.
30. Vermeer C, De Boer-Van den Berg MA: Vitamin K-dependent carboxylase. Hematologia 1985; 18:71-97.
31. Chen H, Egan JO, Chiu JF: Regulation and activities of alpha-fetoprotein. Crit Rev Eukaryotic Gene Expression 1997; 7:11-41.
32. Dohmen K, Shirahama M, Shigematsu H, et al: Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: An evaluation of the local therapeutic effect and survival rate. Hepatogastroenterology 2001; 48:1409-1415.
33. Livraghi T, Giorgio A, Martin G, et al: Hepatocellular carcinoma and cirrhosis in 746 patients; Long-term results of percutaneous ethanol injection. Radiology 1995; 197:101-108.
34. Lencioni R, Bartolozzi C, Caramella D, et al: Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer 1995; 76:1737-1746.
35. Dohmen K, Shigematsu H, Ishibashi H: Trends in clinical characteristics, treatment and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2003; 50:1872-1877.
36. Sakon M, Monden M, Gotoh M, et al: Relationship between pathologic factors and abnormal levels of des-γ-carboxy prothrombin and α-fetoprotein in hepatocellular carcinoma. Am J Surg 1992; 163:251-256.